Guggenheim reiterates Zura Bio stock rating on HS market potential
Guggenheim reiterated a Buy rating and $20 price target for Zura Bio (ZURA), citing potential in its drug Tibulizumab for hidradenitis suppurativa. The stock has gained 17.9% in a week. Guggenheim projects a $14B HS market by 2035, with Tibulizumab potentially capturing 10% of it. Zura Bio reported Q2 2026 earnings and plans to test Tibulizumab for polymyalgia rheumatica. Guggenheim raised its price target from $15 to $20. Wedbush also recommended buying shares ahead of trial results.
How this was made
The 30-second read
Why it matters
The analyst upgrade adds credibility to the company's pipeline and could attract new capital.
Market read
Analyst rating lift provides a near‑term trade idea for a high‑volatility micro‑cap biotech.
What to watch
Potential execution risk of upcoming trials and competition from established IL‑17 inhibitors.
Background
Zura Bio is a pre‑revenue biotech developing tibulizumab for hidradenitis suppurativa and other inflammatory diseases.
Ticker impact
Guggenheim reiterated a Buy rating and raised the price target to $20 for Zura Bio, citing new Q2 earnings and a third indication for tibulizumab.
likely upward pressure as investors price in the higher target and new trial data.
The rating change is a fresh analyst action with a specific price target, providing a clear catalyst for short‑term buying.
Market effects
Positive signal for the broader hidradenitis suppurativa biotech niche.
Limited to U.S. biotech investors.
Minor, confined to niche therapeutic area.
Counterpoint
The stock may be overvalued given its cash burn and pre‑revenue status.
Key entities
- analystGuggenheim
Equity research firm that issued the Buy rating and price target.
- companyZura Bio Ltd.
Biotech developing tibulizumab.
